/stocks — the workspaceLOADING
All KPTISEC filings, by type → · Earnings date & implied move · Search inside filings
Karyopharm Therapeutics Inc. (KPTI) is a pharmaceutical preparations company. Piotroski F-Score 2/7. 2 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-02 from KPTI's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind KPTI’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from KPTI’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on KPTI plus an auto-SWOT — built from KPTI's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate KPTI using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has KPTI been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
No lawmaker has disclosed a trade in KPTI under the STOCK Act.
No tracked institution reported a position in KPTI in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| IWM iShares Russell 2000 ETF | <0.01% | 2026-06-30 |
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Head office: Newton, Massachusetts, United States · the company’s charter and its head office are in different states.
A charter change was filed after this. An 8-K filed 2026-09-18reports an amendment to the company’s articles and a change to shareholder rights (Items 5.03 and 3.03). Reincorporations are reported that way, but so are routine changes such as a new series of preferred stock, and we have not read this one. If it moved the company, the next periodic report’s cover will show it.
Source: the cover page of Karyopharm Therapeutics Inc.’s 10-Q filed 2026-08-13, on EDGAR. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
| Abate KristinChief Accounting Officer | SELL | $0K | view → |
| Poulton StuartEVP, Chief Development Officer | SELL | $1K | view → |
| Mano MichaelEVP, CLO&Secretary | SELL | $3K | view → |
| Paulson Richard A.President and CEO | SELL | $21K | view → |
| Abate KristinChief Accounting Officer | SELL | $1K | view → |
| Cheng Sohanya RoshanEVP & Chief Commercial Officer | SELL | $3K | view → |
| Rangwala ReshmaEVP & Chief Medical Officer | SELL | $4K | view → |
| Poulton StuartEVP, Chief Development Officer | SELL | $4K | view → |
Projected from KPTI's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentKPTI files or announces.
KPTI has sold off after 6 of its last 8 earnings reports.
Each figure is one earnings reaction — how much KPTI moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
KPTI has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+16.4% and -18.1%).
A more typical earnings reaction has been approximately ±7.5%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-13 | -0.5% |
| 2026-05-14 | -13.3% |
| 2026-02-12 | +16.4% |
| 2025-11-03 | -2.6% |
| 2025-08-11 | +2.0% |
| 2025-05-12 | -18.1% |
| 2025-02-19 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -3.2% |
| 2025-01-13 | -11.9% |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.